CrossBridge Bio's pipeline includes a potential best-in-class TROP2-targeting TOP1i/ATRi dual-payloa...
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates
CrossBridge Bio's pipeline includes a potential best-in-class TROP2-targeting TOP1i/ATRi dual-payload ADC anticipated to enter the clinic in 2026.
Author: Business Wire
Read Original Article